Circulating Tumor Cells (CTC) Market

Global Circulating Tumor Cells (CTC) Market:

The global circulating tumor cells (CTC) market size reached USD 12.9 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 27.8 Billion by 2033, exhibiting a growth rate (CAGR) of 8.46% during 2025-2033. The rising prevalence of genetic disorders, owing to lifestyle changes, is propelling the market.

Circulating Tumor Cells (CTC) Market Analysis:

• Major Market Drivers: The inflating need for real-time monitoring and early identification of breast, lung, digestive tract, and prostate cancer is bolstering the market.
• Key Market Trends: The widespread adoption of minimally invasive (MI) diagnostic procedures is acting as a significant growth-inducing factor.
• Competitive Landscape: Some of the prominent companies in the market include BioFluidica Inc., Creatv MicroTech Inc., CytoLumina Technologies Corp., Fluxion Biosciences Inc., Greiner Bio-One International GmbH, Ikonisys Inc., Menarini Silicon Biosystems, Miltenyi Biotec, Qiagen N.V, Rarecells Diagnostics, and Stemcell Technologies, among many others.
• Geographical Trends: The rising investments in medical research to develop cell culture models for disease modeling, genome editing, drug screening, and tumor immunity are contributing to the market in North America.
• Challenges and Opportunities: The high complexity of analysis technologies is hindering the market. However, the development of more affordable, simplified, and high-throughput methods for CTC isolation is expected to fuel the market over the forecasted period.

Circulating Tumor Cells (CTC) Market Trends:

Numerous Liquid Biopsy Advancements

The market is driven by the requirement for minimally invasive methods to monitor and detect cancer through blood samples. Consequently, liquid biopsy technologies provide real-time insights into tumor dynamics and treatment responses, which is gaining extensive traction across the globe. In July 2024, Bio-Rad Laboratories, Inc. launched Celselect Slides 2.0 to enhance rare cell and circulating tumor cell (CTC) capture. Moreover, they enable the processing of greater volumes of liquid biopsy samples for enumeration or use in downstream applications. This is expanding the circulating tumor cells (CTC) market analysis report.

Growing Research Funding

Private investors, government agencies, and pharmaceutical companies are extensively investing in R&D activities. Collaborative efforts between biotech firms, academic institutions, and healthcare providers are fostering the translation of research findings into clinical practice. For example, in January 2024, Dxcover Ltd. initiated three pivotal trials to measure the efficacy of its liquid biopsy platform for early detection of brain, colorectal, and lung cancers to provide the evidence needed to gain regulatory approval and begin commercial operations of its diagnostic technology in the U.S and Europe. This is bolstering the circulating tumor cells (CTC) market outlook report.

Introduction of Technological Advancements

Novel technologies, including next-generation sequencing and advanced imaging systems, are improving the accuracy of CTC detection and analysis. High-throughput automated systems are reducing costs, streamlining workflows, and increasing throughput. In January 2024, Ultima Genomics, Inc., a developer of a revolutionary new ultra-high throughput sequencing architecture, announced the full commercial availability of the UG 100™ at the upcoming advances in genome biology and technology (AGBT).

Global Circulating Tumor Cells (CTC) Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with the circulating tumor cells (CTC) market forecast at the global, regional, and country levels for 2025-2033. Our report has categorized the market based on the technology, application, product, specimen, and end user.

Breakup by Technology:

• CTC Detection and Enrichment Method
• CTC Direct Detection Methods
• CTC Analysis
   

CTC detection and enrichment method dominate the market

The report has provided a detailed breakup and analysis of the market based on the technology. This includes CTC detection and enrichment method, CTC direct detection methods, and CTC analysis. According to the report, the CTC detection and enrichment method represented the largest market segmentation. 

CTC detection and enrichment method enhances the specificity, sensitivity, and efficiency of CTC isolation from blood samples. One of the notable launches is the CellSearch system, the first FDA-approved technology for CTC detection in metastatic breast cancer.

Breakup by Application:

• Clinical/Liquid Biopsy
  • Risk Assessment
  • Screening and Monitoring
• Research
  • Cancer Stem Cell and Tumorigenesis Research
  • Drug/Therapy Development
     

Research currently holds most of the total circulating tumor cells (CTC) market share

The report has provided a detailed breakup and analysis of the market based on the application. This includes clinical/liquid biopsy (risk assessment and screening and monitoring) and research (cancer stem cell and tumorigenesis research and drug/ therapy development). According to the report, research represented the largest market segmentation.

The introduction of cutting-edge methodologies and technologies aimed at enhancing CTC characterization, detection, and clinical application is augmenting the segment's growth.

Breakup by Product:

• Kits and Reagents
• Blood Collection Tubes
• Devices and Systems
   

Devices and systems hold the majority of the global circulating tumor cells (CTC) market demand

The report has provided a detailed breakup and analysis of the market based on the product. This includes kits and reagents, blood collection tubes, and devices and systems. According to the report, devices and systems represented the largest market segmentation.

The inflating need for cancer detection and monitoring is acting as a significant growth-inducing factor. The ClearCell FX system launched a label-free, microfluidic approach that improved cell purity and viability.

Breakup by Specimen:

• Blood
• Bone Marrow
• Other Body Fluids
   

 Blood dominates the circulating tumor cells (CTC) market outlook

The report has provided a detailed breakup and analysis of the market based on the specimen. This includes blood, bone marrow, and other body fluids. According to the report, blood represented the largest market segmentation.

The analysis of circulating tumor cells (CTCs) in the blood stimulates the capabilities and applications of this technology in oncology. For example, the ClearCell FX system gained traction, as it is a novel label-free, microfluidic technique, which enhanced the isolation process.

Breakup by End User:

• Hospital and Clinics
• Research and Academic Institutes
• Diagnostic Centres
   

The report has provided a detailed breakup and analysis of the market based on the end user. This includes hospital and clinics, research and academic institutes and diagnostic centres.

Hospitals and clinics need enhanced patient care through more personalized and timely interventions. Research and academic institutes leverage CTC technologies to understand tumor biology, advance cancer research, and develop new therapeutic strategies. Diagnostic centers further offer early cancer detection and monitoring of treatment efficacy. As per the circulating tumor cells (CTC) market forecast report, this is acting as a significant growth-inducing factor.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

North America exhibits a clear dominance in the market

The circulating tumor cells (CTC) market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

The increasing prevalence of cancer is augmenting the market. Moreover, the escalating demand for cancer immunotherapy in the United States will continue to fuel the market in the coming years. According to the IMARC, the United States cancer immunotherapy market size is expected to exhibit a growth rate (CAGR) of approximately 10.90% during 2024-2032. 

Competitive Landscape:

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major market companies have also been provided. Some of the key players in the market include:

• BioFluidica Inc
• Creatv MicroTech Inc.
• CytoLumina Technologies Corp.
• Fluxion Biosciences Inc.
• Greiner Bio-One International GmbH
• Ikonisys Inc
• Menarini Silicon Biosystems
• Miltenyi Biotec
• Qiagen N.V
• Rarecells Diagnostics
• Stemcell Technologies
   

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

Circulating Tumor Cells (CTC) Market Recent Developments:

• July 2024: Bio-Rad Laboratories, Inc. launched Celselect Slides 2.0 to enhance rare cell and circulating tumor cells (CTC) capture. Moreover, they enable the processing of greater volumes of liquid biopsy samples for enumeration or use in downstream applications.
• January 2024: Dxcover Ltd. initiated three pivotal trials to measure the efficacy of its liquid biopsy platform for early detection of brain, colorectal, and lung cancers to provide the evidence needed to gain regulatory approval and begin commercial operations of its diagnostic technology in the U.S. and Europe.
• January 2024: Ultima Genomics, Inc., a developer of a revolutionary new ultra-high throughput sequencing architecture, announced the full commercial availability of the UG 100™ at the upcoming advances in genome biology and technology (AGBT).

Circulating Tumor Cells (CTC) Market Report Scope:

Key Benefits for Stakeholders:

• IMARC's industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the circulating tumor cells (CTC) market from 2019-2033.
• The research report provides the latest information on the market drivers, challenges, and opportunities in the global circulating tumor cells (CTC) market.
• The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
• Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the circulating tumor cells (CTC) industry and its attractiveness.
• The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.